Copyright
©The Author(s) 2020.
World J Gastroenterol. Nov 7, 2020; 26(41): 6455-6474
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6455
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6455
Table 7 Summary of the results of undiscounted and discounted point estimations of measured outcomes in base case analysis comparing infliximab maintenance therapy vs conventional maintenance therapy in the constructed decision analytic model
Model outputs | Results of base-case analysis without discounting | Results of base-case analysis with discounting | ||||
IMT | CMT | Difference | IMT | CMT | Difference | |
Overall survival in yr | 43.815 | 40.944 | 2.871 | 23.858 | 22.947 | 0.911 |
Disease remission before surgery | 30.433 | 13.157 | 17.276 | 18.102 | 9.392 | 8.710 |
Active disease before surgery | 1.398 | 2.540 | -1.142 | 0.803 | 1.788 | -0.985 |
Disease remission after surgery | 11.407 | 20.893 | -9.486 | 4.709 | 9.701 | -4.993 |
Active disease after surgery | 0.576 | 4.354 | -3.777 | 0.244 | 2.066 | -1.821 |
Total QALY | 33.365 | 30.889 | 2.476 | 18.392 | 17.491 | 0.901 |
Disease remission before surgery | 23.450 | 10.220 | 13.230 | 14.066 | 7.288 | 6.778 |
Active disease before surgery | 0.973 | 1.803 | -0.831 | 0.566 | 1.278 | -0.711 |
Disease remission after surgery | 8.553 | 15.889 | -7.335 | 3.592 | 7.492 | -3.900 |
Active disease after surgery | 0.389 | 2.977 | -2.588 | 0.168 | 1.433 | -1.266 |
Total reimbursed medical costs | ¥469958 | ¥373757 | ¥96201 | ¥242107 | ¥192336 | ¥49771 |
Drug costs | ¥156606 | ¥48359 | ¥108246 | ¥84553 | ¥25062 | ¥59491 |
Surgery costs | ¥8261 | ¥28346 | -¥20085 | ¥4019 | ¥14511 | -¥10492 |
Disease remission management | ¥284675 | ¥226987 | ¥57687 | ¥143601 | ¥116897 | ¥26704 |
Active disease management | ¥20417 | ¥70065 | -¥49648 | ¥9934 | ¥35866 | -¥25932 |
Total patient out-of-pocket costs | ¥726433 | ¥163918 | ¥562515 | ¥431392 | ¥109111 | ¥322281 |
Drug costs | ¥629970 | ¥27629 | ¥602340 | ¥374967 | ¥18346 | ¥356622 |
Surgery costs | ¥2526 | ¥11736 | -¥9210 | ¥1452 | ¥7840 | -¥6387 |
Disease remission management | ¥87695 | ¥95541 | -¥7846 | ¥51383 | ¥63547 | -¥12165 |
Active disease management | ¥6243 | ¥29012 | -¥22769 | ¥3590 | ¥19378 | -¥15789 |
Total medical costs | ¥1196392 | ¥537676 | ¥658716 | ¥673499 | ¥301447 | ¥372052 |
- Citation: Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474
- URL: https://www.wjgnet.com/1007-9327/full/v26/i41/6455.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i41.6455